Kun‐Ho Yoon

Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial

William T. Cefalu, Lawrence A. Leiter, Kun‐Ho Yoon et al. · The Lancet · 2013 · 718 citations

Metabolic Syndrome, Diabetes Management, Canagliflozin Versus Glimepiride +8

Selective β-Cell Loss and α-Cell Expansion in Patients with Type 2 Diabetes Mellitus in Korea

Kun‐Ho Yoon, Seung‐Hyun Ko, Jae‐Hyoung Cho et al. · The Journal of Clinical Endocrinology & Metabolism · 2003 · 645 citations · Full text

Pathology, Surgery, Pancreas Transplantation +19

Loss of Autophagy Diminishes Pancreatic β Cell Mass and Function with Resultant Hyperglycemia

Hye Seung Jung, Kun Wook Chung, Jeong Won Kim et al. · Cell Metabolism · 2008 · 631 citations · Full text

Obesity, Metabolic Syndrome, Cell Autophagy +9

Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial

Hiddo J.L. Heerspink, Hans‐Henrik Parving, Dennis L. Andress et al. · The Lancet · 2019 · 589 citations · Full text

Urology, Renal Disease, Renal Events +7

Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24‐week, double‐blind, placebo‐controlled trial

Krzysztof Strojek, Kun‐Ho Yoon, Veronika Hrubá et al. · Diabetes Obesity and Metabolism · 2011 · 409 citations